Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
Source: SeekingAlpha
2026-01-24 02:08:31 ET
Although systemic complement-mediated diseases are, fortunately, relatively rare, there is a wider range of diseases where complement overactivation plays a significant role, and these are often hard-to-treat diseases with serious quality of life implications. Annexon ( ANNX ) is looking to change this with a pipeline of risky, but high-potential, drugs targeting the C1q protein in a range of indications....
Read the full article on Seeking Alpha
For further details see:
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
Annexon Inc.
NASDAQ: ANNX
ANNX Trading
7.86% G/L:
$5.43 Last:
1,006,654 Volume:
$5.02 Open:
ANNX Latest News
February 24, 2026 08:00:00 am
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 17, 2026 08:00:00 am
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
ANNX Stock Data
$671,140,030
105,432,390
8.18%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
Brisbane
